Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

2.250 +0.020 (+0.90%)
Streaming Delayed Price Updated: 10:23 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 356,512
Open 2.250
Bid (Size) 2.240 (21)
Ask (Size) 2.250 (23)
Prev. Close 2.230
Today's Range 2.200 - 2.270
52wk Range 1.430 - 6.520
Shares Outstanding 112,714,488
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
From Coherus BioSciences, Inc.
Via GlobeNewswire

Performance

YTD
-28.34%
-28.34%
1 Month
-10.36%
-10.36%
3 Month
-3.02%
-3.02%
6 Month
+10.84%
+10.84%
1 Year
-61.93%
-61.93%

More News

Read More
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Recap: Coherus BioSciences Q4 Earnings
Via Benzinga
Earnings Preview For Coherus BioSciences
Via Benzinga
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus Biosciences Stock Tumbled on Thursday
Via The Motley Fool
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2024
Via Benzinga
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Jumped Today
Via The Motley Fool
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Is Sinking Today
Via The Motley Fool
Why Coherus Biosciences Popped Today
Via The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Via Benzinga
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
Via InvestorPlace
Why Is B. Riley Financial (RILY) Stock Down 11% Today?
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
Via InvestorPlace
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.